Core Viewpoint - The company, Meihua Biological Technology Group Co., Ltd., has announced its 2025 semi-annual operating data and strategic plans, emphasizing its focus on enhancing operational quality, expanding international presence, and maintaining investor returns. Company Overview - Meihua Biological Technology Group Co., Ltd. is engaged in the amino acid industry, focusing on synthetic biology technology as its core [32]. - The company reported a slight decrease in revenue of 2.87% year-on-year, totaling 12.28 billion yuan, while net profit increased by 19.96% to 1.768 billion yuan [32]. Financial Data - The company plans to upgrade production capacity and expand its scale, with project expenditures of 1.087 billion yuan in the first half of 2025 [33]. - The company has a history of stable cash dividends, distributing a total of 2.27 billion yuan in dividends for the 2024 fiscal year, which is approximately 83% of the net profit attributable to shareholders [38]. Strategic Initiatives - The company aims to enhance its global competitiveness through a significant acquisition of amino acid and HMO business assets from a Japanese company, adding over 30 patent families and expanding its product line [34]. - The company is committed to digital transformation, with plans to implement a standardized MES system across its production bases by the third quarter of 2025 [35]. Investor Relations - The company emphasizes transparent communication with investors, planning a semi-annual performance briefing on September 1, 2025, to address investor concerns and enhance engagement [45][47]. - The company has established a robust investor communication system to ensure timely and accurate information dissemination [39]. Governance and Compliance - The company is focused on improving its governance structure and compliance with regulations, including the potential restructuring of its supervisory board [40][41]. - The company has implemented a long-term incentive plan for its management team to align their interests with those of shareholders [42].

（编辑 李家琪） 证券日报网讯 8月19日晚间，梅花生物发布公告称，公司拟选聘容诚会计师事务所为公司2025年度财务 报告审计机构及内部控制审计机构，并提请股东大会授权公司管理层根据2025年度审计的具体工作量及 市场价格水平确定其年度审计费用。本次拟聘任会计师事务所事项符合《国有企业、上市公司选聘会计 师事务所管理办法》等有关规定。公司审计委员会、董事会对本次拟选聘会计师事务所的事项均不存在 异议，前任会计师明确知悉并无异议，该事项尚需提交股东大会审议。 ...

Group 1 - The company, Meihua Biological, announced the approval of multiple proposals during the 20th meeting of its 10th Board of Directors, including the proposal for the 2025 semi-annual report and its summary [2]

Core Insights - The company reported a revenue of 12.28 billion yuan for the first half of 2025, a year-on-year decrease of 2.9% [2] - The net profit attributable to the parent company was 1.77 billion yuan, reflecting a year-on-year increase of 20.0% [2] Company Performance - The company is recognized as a leading player in the global amino acid industry, focusing on a diversified product matrix centered around amino acids, including animal nutrition amino acids, flavor enhancers, pharmaceutical amino acids, and colloidal polysaccharides [2] - Key products such as monosodium glutamate, 98% lysine, and feed-grade isoleucine saw an increase in sales volume during the reporting period [2] - The increase in revenue and gross profit was driven by a rise in both volume and price of 70% lysine, alongside a decrease in major material costs and improved production metrics, resulting in a gross profit increase of 382 million yuan [2]

Core Insights - The company reported a revenue of 12.28 billion yuan for the first half of 2025, a decrease of 2.87% year-on-year [1] - The net profit attributable to shareholders reached 1.768 billion yuan, an increase of 19.96% year-on-year, while the net profit excluding non-recurring items was 1.628 billion yuan, up 24.98% year-on-year [1] - The growth in sales volume of key products such as monosodium glutamate, 98% lysine, and feed-grade isoleucine contributed to the revenue increase, while the decline in market prices for some main products led to a decrease in main business revenue [1] Revenue Analysis - The decrease in revenue was attributed to lower market prices for main products like monosodium glutamate, xanthan gum, and threonine, despite increased sales volume from the company's subsidiaries [1] - The increase in revenue from 70% lysine was driven by both volume and price growth, alongside a rise in sales volume of 98% lysine [1] Cost and Profitability - The company experienced a reduction in production costs due to lower material costs and improved production metrics, resulting in a gross profit increase of 382 million yuan [1] - The gross profit increase contributed significantly to the overall net profit growth during the reporting period [1]

Group 1 - The core viewpoint of the article highlights that Meihua Biological has reported a slight decline in revenue while achieving significant profit growth in the first half of 2025 [1] - The company's operating revenue for the first half of 2025 was 12.28 billion yuan, a year-on-year decrease of 2.9% [1] - The net profit attributable to the parent company reached 1.77 billion yuan, reflecting a year-on-year increase of 20.0% [1] Group 2 - Meihua Biological is recognized as a leading enterprise in the global amino acid industry, focusing on a diversified product matrix centered around amino acids [1] - The company has leveraged its advantages in synthetic biology technology to develop a range of products, including animal nutrition amino acids, flavor enhancers, pharmaceutical amino acids, and colloidal polysaccharides [1] - During the reporting period, sales of key products such as monosodium glutamate, 98% lysine, and feed-grade isoleucine increased, contributing to revenue growth [1] - The increase in lysine sales volume and price, which rose by 70%, led to higher revenue and gross profit [1] - A decrease in the cost of main materials and improvements in production metrics contributed to a reduction in production costs, resulting in an increase in gross profit by 382 million yuan, which in turn boosted the company's net profit [1]

Group 1 - The company achieved operating revenue of 12.28 billion in the first half of 2025, representing a year-on-year decrease of 2.87% [1] - The net profit attributable to shareholders of the listed company was 1.768 billion, showing a year-on-year increase of 19.96% [1]

证券代码：600873 证券简称：梅花生物 公告编号：2025-050 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 拟聘任的会计师事务所名称：容诚会计师事务所（特殊普通合伙）（以下 简称"容诚会计师事务所"）。 原聘任的会计师事务所名称：政旦志远（深圳）会计师事务所（特殊普 通合伙）（以下简称"政旦志远"）。 变更会计师事务所的简要原因：综合考虑梅花生物科技集团股份有限公 司（以下简称"公司"）业务发展情况和整体审计的需要，为保证审计工作的独立 性、客观性、公允性，公司拟选聘容诚会计师事务所为公司 2025 年度财务报告 审计机构及内部控制审计机构，并提请股东大会授权公司管理层根据 2025 年度审 计的具体工作量及市场价格水平确定其年度审计费用。本次拟聘任会计师事务所 事项符合《国有企业、上市公司选聘会计师事务所管理办法》等有关规定。公司 审计委员会、董事会对本次拟选聘会计师事务所的事项均不存在异议，前任会计 师明确知悉并无异议，该事项尚需提交股东大会审议。 一、拟聘任会计师事务所的基本情况 （一） ...

梅花生物科技集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600873 证券简称：梅花生物 公告编号：2025-052 梅花生物科技集团股份有限公司（以下简称"公司"）已发布 2025 年半年度 报告，为便于广大投资者更全面深入地了解公司 2025 年上半年度经营成果、财 务状况，公司计划于 2025 年 9 月 1 日（星期一）10:00-11:00 举行 2025 年半年度 业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年上半年的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 会议召开时间：2025 年 9 月 1 日 （星期一） 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互 ...

证券代码：600873 证券简称：梅花生物 公告编号：2025-051 梅花生物科技集团股份有限公司 关于 2025 年度"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》要求，积极 响应上海证券交易所《关于开展沪市公司"提质增效重回报"专项行动的倡议》， 推动公司实现高质量发展，切实保障和维护投资者合法权益，进一步增强投资者 信心，梅花生物科技集团股份有限公司（以下简称"公司"）结合公司实际经营 情况及未来发展战略，制定了《2025 年度"提质增效重回报"行动方案》（以下 简称"本行动方案"），本行动方案已经公司第十届董事会第二十次会议审议通过， 具体如下： 一、聚焦主营业务，持续提升经营质量 通过此次跨境并购，公司新增 30+专利家族的核心知识产权及多种氨基酸新 品类和新菌种，公司产业链成功向下游高附加值医药级氨基酸市场延伸，氨基酸 产品管线进一步丰富并新增 HMO 管线。此外，公司还新增上海、泰国、德国、 日本、北美等多处生产运营实体 ...